Table 1 Baseline characteristics
Standard (N=20) HPSD (N=100) P
Age (mean ± SD, min-max) 66.4 ± 10 (45 - 80) 66,4 ± 10 (35 - 80)
0,99
Sex male female 7/20 (35%) 13/20 (65%) 60/100 (60%) 40/100 (40%)
0,04
LV-EF (mean ± SD, min-max) 59.5 ± 5.5 (45 - 65) 54.2 ± 13.3 (10 - 65)
0,08
AF type paroxysmal persistent 9/20 (45%) 11/20 (55%) 49/100 (49%) 51/100 (51)
0.74
EHRA stage I: IIa: IIb: III: IV: 0/20 (0%) 1/20 (5%) 5/20 (25%) 11/20 (55%) 3/20 (15%) 1/100 (1%) 8/100 (8%) 26/100 (26%) 56/100 (56%) 9/100 (9%)
0.94
CHA2DS2-VASc (mean ± SD, min-max)
3.2 ± 1.5 (1 - 6) 2.8 ± 1.5 (0 - 7)
0,34
Medications Betablockers Flecainide Amiodarone 19/20 (95%) 1/20 (5%) 5/20 (25%) 89/100 (89%) 6/100 (6%) 24/100 (24%) 0.41 0.86 0.92